Thermo Fisher Bioproduction Insights
-
Manufacturing CAR T Cell Therapies: Challenges, Insights And Solutions
6/16/2025
Manufacturing patient-specific cell therapies is a complex, multi-step process. Addressing key hurdles in production time, scalability, and cost is crucial to making these vital treatments more accessible.
-
Raw Material Considerations For Cell Therapies
6/16/2025
For cell therapy developers, selecting appropriate raw materials is a significant challenge. Examine key considerations for mitigating risk and aligning with current regulatory expectations.
-
Next-Gen Biomanufacturing: Process Intensification For mAb Production
6/13/2025
Intensified processes, omics-driven media, and advanced bioreactors can boost efficiency and scalability in mAb production.
-
Improved T Cell Expansion Using Closed, Automated Stirred-Tank Bioreactors
6/10/2025
A shift from traditional rocking motion systems to stirred-tank bioreactors can enhance T cell expansion, offering greater scalability and more intimate process control.
-
Comparing Serum-free To Serum-Supplemented Media
6/9/2025
Reducing serum in vaccine manufacturing is a key consideration for lowering costs and improving supply security. We compare performance in serum-free versus serum-supplemented media.
-
A Temperature-Stable Replacement For Animal Trypsin In Cell Dissociation Applications
6/9/2025
Improve cell dissociation with a gentle, recombinant enzyme. This temperature-stable protease shows dissociation kinetics similar to porcine trypsin but with lower cell toxicity and greater overall purity.
-
Exploring The Challenges Of Cell Dissociation In Vaccine Manufacturing
6/9/2025
Vaccine manufacturing relies on efficient cell dissociation methods. Explore the challenges of traditional approaches like trypsin and the benefits of animal origin-free alternatives for improved workflows.
-
Master The Course In Cell Culture
6/9/2025
Learn how to navigate the complexities of mAb production with actionable strategies for quality-driven processes, supplier selection, and future-proofing your biologic manufacturing systems.
-
Streamline Your mAb Manufacturing With Strategic Development And CDMO Compatibility
6/4/2025
Though the journey to mAb development begins at lab scale, for clinical trials and commercial distribution, a production process must be streamlined and scalable to 2,000 L production and above.
-
Animal-Origin Free Peptones In Cell Culture Media For Viral Vaccine Manufacturing
5/27/2025
Investigate the impact of peptone supplementation on adenovirus and VSV production, highlighting its potential to reduce serum dependency in cell culture media.